• DOI:10.1038/ng.478
Corpus ID: 21293339

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

@article{Ross2009GeneticVI,
  title={Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy},
  author={C. Ross and Hagit Katzov-Eckert and M. Dub{\'e} and B. Brooks and S. Rassekh and A. Barhdadi and Yassamin Feroz-Zada and H. Visscher and A. Brown and M. Rieder and P. Rogers and M. Phillips and B. Carleton and M. Hayden},
  journal={Nature Genetics},
  year={2009},
  volume={41},
  pages={1345-1349}
}

C. Ross, Hagit Katzov-Eckert, +11 authors M. Hayden

Published 2009

Biology, Medicine

Nature Genetics

Cisplatin is a widely used and effective chemotherapeutic agent, although its use is restricted by the high incidence of irreversible ototoxicity associated with it. In children, cisplatin ototoxicity is a serious and pervasive problem, affecting more than 60% of those receiving cisplatin and compromising language and cognitive development. Candidate gene studies have previously reported associations of cisplatin ototoxicity with genetic variants in the genes encoding glutathione S-transferases… CONTINUE READING

View on Nature

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed